stella
beta
Personalized vs. Fixed-Activity 177Lu-PSMA-617 Radiopharmaceutical Therapy (PRODIGY-2) — Stella
Recruiting
Back to Metastatic Castrate Resistant Prostate Cancer (mCRPC) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(1 site)
Canada
CHU de Québec-Université Laval, Québec, Quebec
View full record on ClinicalTrials.gov